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Abstract
Background: Neural stem cells for the treatment of spinal cord injury (SCI) are of particular interest for future
therapeutic use. However, until now, stem cell therapies are often limited due to the inhibitory environment
following the injury. Therefore, in this study, we aimed at testing a combinatorial approach with BDNF (brain-derived
neurotrophic factor) overexpressing early neural progenitors derived from mouse embryonic stem cells. BDNF
is a neurotrophin, which both facilitates neural differentiation of stem cells and favors regeneration of
damaged axons.
Methods: Mouse embryonic stem cells, modified to stably express BDNF-GFP, were differentiated into
PSA-NCAM positive progenitors, which were enriched, and SSEA1 depleted by a sequential procedure of
magnetic-activated and fluorescence-activated cell sorting. Purified cells were injected into the lesion core
seven days after contusion injury of the spinal cord in mice, and the Basso mouse scale (BMS) test to
evaluate motor function was performed for 5 weeks after transplantation. To analyze axonal regeneration the
anterograde tracer biotinylated dextran amine was injected into the sensorimotor cortex two weeks prior to
tissue analysis. Cellular differentiation was analyzed by immunohistochemistry of spinal cord sections.
Results: Motor function was significantly improved in animals obtaining transplanted BDNF-GFP-overexpressing cells
as compared to GFP-expressing cells and vehicle controls. Stem cell differentiation in vivo revealed an increase of
neuronal and oligodendrocytic lineage differentiation by BDNF as evaluated by immunohistochemistry of the neuronal
marker MAP2 (microtubule associated protein 2) and the oligodendrocytic markers ASPA (aspartoacylase) and Olig2
(oligodendrocyte transcription factor 2). Furthermore, axonal tracing showed a significant increase of biotin dextran
amine positive corticospinal tract fibers in BDNF-GFP-cell transplanted animals caudally to the lesion site.
Conclusions: The combinatorial therapy approach by transplanting BDNF-overexpressing neural progenitors improved
motor function in a mouse contusion model of SCI. Histologically, we observed enhanced neuronal and
oligodendrocytic differentiation of progenitors as well as enhanced axonal regeneration.
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Background
Spinal cord injury (SCI) is in most cases caused by con-
tusion and compression of the spinal cord, leading to
complete or incomplete loss of motoric and sensory
functions. Besides the lack of neuronal regeneration of
severed axons owing to inhibitory molecules, massive
cell death occurs in particular of neurons and oligoden-
drocytes. Death of oligodendrocytes can be regarded as
particularly harmful, because this can lead secondarily to
demyelination of spared, intact axons, in cases of preva-
lent incomplete injury [1].
Cell therapy is regarded as one potential therapeutic
approach for SCI. Diverse cell types have been tested
already in transplantation studies in SCI animals, such
as Schwann cells, olfactory ensheathing cells, mesenchy-
mal stem cells, and embryonal stem cells [2]. However,
none of these cell types led to a striking functional mo-
toric improvement. Hereby, embryonic stem cells (ESCs)
(differentiated into neural stem cells (NSCs)) were the
most promising cell source, because they could at least
lead to a moderate functional improvement [3–6]. The
advantage of ESCs compared with other cell types, such
as adult stem cells (e.g., mesenchymal stem cells) or
other somatic cells (e.g., Schwann cells or olfactory en-
sheathing cells), is their high differentiation potential in
diverse cell types and their better survival rate in vivo.
However, the only moderate improved function could
possibly be explained by the fact that not enough ESCs
have differentiated into the required specialized cell type
or that cell replacement was not sufficient to compen-
sate for the limited regeneration potential of the spinal
cord. Combinatorial approaches (e.g., coapplication of
neurotrophins) might therefore be necessary for complete
functional restoration. The neurotrophin brain-derived
neurotrophic factor (BDNF) is a secreted growth-pro-
moting (“trophic”) protein which is particularly important
for neuronal survival and differentiation [7–10]. Further-
more, it is known that BDNF is important for oligo-
dendroglial proliferation, differentiation, and myelination
[11–13]. In addition, by using BDNF-secreting fibroblasts
or by viral delivery, BDNF was shown to have a positive
effect on axonal regeneration [14–17] and to enhance the
integration of transplanted embryonal precursor cells [18].
In a previous study [19], we demonstrated that ESCs
stably expressing BDNF–green fluorescent protein
(GFP) display an enhanced neuronal differentiation in
vitro. The current study addresses the use of these
ESCs in a contusion mouse model of SCI. This ap-
proach involves a combination therapy using ESC-
derived polysialylated neural cell adhesion molecule
(PSA-NCAM)-positive neural progenitors, which first
have the potential to differentiate into neurons and oli-
godendrocytes [20], and second guarantee a long-term
exogenous supply of BDNF. Here, we report that
BDNF-overexpressing transplanted progenitors differ-
entiated in vivo to an increased extent into neurons
and oligodendrocytes compared with control cells. Fur-
thermore, the numbers of corticospinal tract (CST) fi-
bers caudal to the lesion site were enhanced by
transplantation of BDNF-overexpressing progenitors,
indicative for axonal regeneration. As a result of histo-
pathological improvements, recovery of motor function
was obtained only in the group transplanted with
BDNF-overexpressing progenitors. Tests for mechan-
ical induced allodynia revealed that high expression of
BDNF was not harmful in terms of pain threshold. Fur-
thermore, we did not observe any tumor formation be-
cause we used a defined protocol of ESC differentiation
(modified from [21]) and subsequent purifications to




C57BL/6 mouse ESCs were modified by knock-in tech-
nology into the Rosa26 locus to overexpress either
BDNF-GFP or GFP as described previously [19]. ESCs
were maintained on feeder cells (mouse embryonic fi-
broblasts) and cultured in the presence of leukemia in-
hibitory factor (LIF) under standard conditions [23]. For
differentiation, cells were cultured for two passages on
gelatin and then differentiated according to the protocol
of [21] with minor modifications to yield PSA-NCAM-
positive neural progenitors. Briefly, cells were dissociated
and reaggregated to form embryoid bodies (EBs) for
6 days on nonadherent bacterial-grade dishes. EBs were
then plated on adherent dishes and kept in ITSFn
medium (insulin, transferrin, selenium, and fibronectin)
in Dulbecco’s modified Eagle’s medium (DMEM)/F12 to
select for Nestin-positive cells. After 8 days, cells were
trypsinized and replated onto dishes coated with poly-
ornithin/laminin (Sigma Aldrich, St. Louis, MO, USA) at
a density of 1.5 × 105 cells/cm2 in DMEM/F12/Glutamax
supplemented with B27 (all from Invitrogen, Carlsbad,
CA, USA) and 10 ng/ml basic fibroblast growth factor
(bFGF; Sigma Aldrich). Cells were expanded for 6 days.
Thereafter, cells were purified by the sequential use of
magnetic-activated cell sorting (MACS; Miltenyi Biotec,
Bergisch Gladbach, Germany) and fluorescence-activated
cell sorting (FACS) technology.
Purification of progenitors by MACS and FACS
MACS
MACS (Miltenyi Biotec) purification was performed in
two steps. First, undifferentiated ESCs were labeled with
anti-stage-specific embryonic antigen-1 (anti-SSEA-1)
magnetic MicroBeads to remove undifferentiated ESCs
with tumorigenic potential. After trypzination of cells,
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20 μl anti-SSEA-1 MicroBeads/107 cells were added and
incubated for 15 minutes at 4 °C. After washing and re-
suspension in MACS buffer, labeled cells were applied to
the LD Column and the flow through (unlabeled cells)
was collected. Second, PSA-NCAM-positive progenitors
were enriched by incubating the SSEA-1-negative cell
population with 10 μl PSA-NCAM-allophycocyanin
(APC)/107 cells for 10 minutes at 4 °C. Then, 20 μl anti-
APC magnetic MicroBeads/107 cells were added. After
15 minutes of incubation at 4 °C, cells were washed and
resuspended in MACS PB buffer, and then applied to
the LS Column. PSA-NCAM-positive cells retained in
the column and were collected by removal of the magnet
from the column.
FACS
To further increase the purity of the MACS-enriched
PSA-NCAM-positive cell population, PSA-NCAM-APC-
labeled cells were incubated with r-phycoerythrin (PE)-
conjugated SSEA-1 antibody (Stemgent, Cambridge, MA,
USA) for 1 hour at 4 °C. Cells were washed with Dulbec-
co’s Phosphate-Buffered Saline (DPBS), resuspended in
DPBS (7 × 106 cells/ml for sorting), and filtered through a
30 μm preseparation filter. Stained cells were sorted on a
fluorescence-activated cell sorter BD FACSAria™ III, using
FACSDiva™ Software (BD Biosciences, Heidelberg,
Germany). The sorting speed was adjusted to ensure sort-
ing efficiency above 90 %. Forward scattering and side
scattering excluded debris and dead cells. The following
negative controls were used to identify the population of
interest: unstained cells before MACS; stained cells with
SSEA-1 antibody before MACS; and PSA-NCAM-APC
only (cells after PSA-NCAM enrichment, no SSEA-1
stain). SSEA-1–/PSA-NCAM+ FACS sorted cells were
plated onto poly-ornithin/laminin coated dishes at a dens-
ity of 1.5 × 105 cells/cm2.
Flow cytometric analysis and immunocytochemistry
To determine the amount of PSA-NCAM and SSEA-1-
positive cells in the expansion culture, cells were ana-
lyzed via flow cytometry and immunofluorescence. The
following antibodies were used: primary mouse IgM
monoclonal PSA-NCAM (1:100; Chemicon, Billerica,
MA, USA), primary mouse IgM monoclonal SSEA-1
(1:50; Developmental Studies Hybridoma Bank, University
of Iowa, Iowa City, IA, USA), or secondary antibody anti-
mouse AlexaFluor546 IgM (1:1000; Invitrogen).
For flow cytometric analysis before MACS/FACS puri-
fication, cells were trypsinized and gently triturated.
Cells were filtered through a 30 μm preseparation filter
to obtain single cell suspensions. Then 1 × 106 cells were
fixed for 15 minutes with 4 % paraformaldehyde (PFA),
washed, and incubated with the primary antibody for
1 hour. Subsequently, cells were incubated with the
secondary antibody for 45 minutes. All washing and in-
cubation steps were performed in 0.5 % bovine serum al-
bumin/phosphate-buffered saline (PBS) at room
temperature. Stained cells were analyzed on a flow cyt-
ometer (BD LSRFortessa™). PSA-NCAM and SSEA-1
positivity was determined according to negative controls
where no primary antibody was used and by comparison
with undifferentiated ESCs, which do not express PSA-
NCAM but SSEA-1.
For immunofluorescence staining before and after
MACS/FACS purification, cells were fixed in 4 % PFA
for 15 minutes, rinsed with PBS, and incubated in 4 %
goat serum in PBS for 15 minutes. Cells were then incu-
bated with primary antibodies in 4 % goat serum over-
night at 4 °C. After 3 × 5 minute PBS washes, cells were
incubated with the secondary antibody for 1 hour at
room temperature. After rinsing with PBS, 4′,6-diami-
dino-2-phenylindol (DAPI) was used for nuclear coun-
terstaining and coverslips were mounted with Mowiol.
For immunofluorescence of 5-bromo-2′-deoxyuridine
(BrdU)-treated cells before transplantation, cells were
processed according to BrdU immunohistochemistry of
spinal cord sections.
BrdU treatment of cells and preparation of cells for
transplantation
To ensure cell detection after transplantation, cells were la-
beled with BrdU (Sigma Aldrich). One day after FACS sort-
ing, cells were incubated with 1 μg/ml BrdU for 48 hours.
For transplantation, cells were trypsinized, washed with
DPBS, and resuspended in Hank’s Balanced Salt Solution
without calcium and magnesium (HBSS w/o Ca2+/Mg2+;
Sigma Aldrich) at a concentration of 1 × 105 cells/μl.
Animals and contusion SCI
All surgical interventions and animal care were provided
in accordance with the German Committee on Animal
Health and Care of Rhineland-Palatinate (application
number: G 14-1-012).
Thirteen-week-old male C57BL/6 mice were analgized
(Rimadyl, Pfizer, New York City, NY, USA, 4 mg/kg;)
and anesthetized with 3 % isoflurane, and the spinal cord
was exposed at the T8 vertebral level via a laminectomy.
With a stereotactic system and a blunt knife (2 mm
long, 1 mm wide), a force of 30 × g for 1 minute was
placed on the spinal cord to induce a severe contusion
injury. Sham mice were not subjected to a contusion in-
jury but to a laminectomy. The inner suture was per-
formed with an atraumatic suture material. The skin
suture was closed with a reflex wound clip system. Post-
surgical care included at least 10 days of subcutaneous
saline injection to maintain hydration and manual blad-
der expression once a day until spontaneous voiding
returned.
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Transplantation
Seven days after surgery, mice were either treated with
vehicle injection (HBSS w/o Ca2+/Mg2+) or received
cell transplants directly into the lesion core. Mice were
analgized and anaesthetized as described for contusion
surgery. After disinfection of the back skin the suture
was reopened. Then 1 μl HBSS w/o Ca2+/Mg2+ or 1 ×
105 cells/μl HBSS w/o Ca2+/Mg2+ were injected by self-
made glass capillary with a tip 70–90 μm in diameter
configured to a 10 μl Hamilton syringe and a small ani-
mal stereotaxic injection system (David Kopf Instru-
ments, Tujunga, CA, USA). The cell suspension or
vehicle solution was injected into the lesion core at the
T8 level over a 5-minute period with an injection rate
of 200 nl/minute. The syringe was maintained in place
for an additional 5 minutes to prevent back-flux from
the injection site. The surgery site was closed as already
described.
Anterograde tracing
Sixteen days prior to processing the animals for histo-
logical analysis, the nontoxic, axonal tracer biotinylated
dextran amine (BDA) was injected into the sensorimotor
cortex. After shaving and disinfection of the skin, the
scalp was removed by cutting in a rostrocaudal
direction.
Injection coordinates were 1.0 mm lateral to the midline
at 0.5 mm anterior, 0.5 mm posterior, and 1.0 mm poster-
ior to bregma at a depth of 0.5 mm from the cortical sur-
face. Six small holes were drilled in the skull over the
sensorimotor cortex. Then 0.2 μl tetramethylrhodamine
and biotin-conjugated dextran amine (10,000 MW, lysine
(mini ruby); Invitrogen) was injected per injection hole
into the sensorimotor cortex with a 10 μl Hamilton syr-
inge fitted with a pulled glass capillary. The skin suture
was closed with a reflex wound clip system. For analysis of
tracing, see Microscopic analysis of histology.
Behavioral assays
Basso mouse scale
To assess motor function of the hindlimbs, the Basso
mouse scale (BMS) was used [24]. All mice were pre-
trained and tested in a round open field (120 cm in
diameter) preoperatively, 24 hours after SCI and at least
weekly for up to 42 days post operation (DPO). Two in-
dependent raters, who were blinded to the experimental
conditions, evaluated functional recovery using the BMS.
Each mouse was observed separately for 4 minutes in
each session and hindlimb movements were assessed
with the scale ranging from 0 (no ankle movement) to 9
(complete functional recovery) points. The two scores
for left and right hindpaws were averaged to obtain a
single value per mouse, which represents the mobility of
the mouse. Mice with a BMS score higher than 3 at
24 hours after injury were excluded from future evalu-
ation (n = 2).
Von Frey filament test
Mechanical allodynia was tested using the von Frey fila-
ment test, which measures nociceptive responses in ro-
dents after application of a non-noxious mechanical
stimulus to the hindpaw. The frequency of paw with-
drawal was measured by stimulating the plantar surface
of the right and left hindpaws with filaments of differ-
ent weight (filament weight range 0.6–8.0 g; Ugo Basile,
Varese, Italy). The pain threshold was established using
the up–down method as described previously [25]. The
test was carried out in all mice 42 days after SCI. The
mouse was placed in a clear plastic box with a metal
mesh floor and was allowed to habituate to the experi-
mental environment for 45 minutes before carrying out
the test. Von Frey filaments were then applied from
underneath the metal mesh floor to stimulate the plan-
tar surface of the paw.
The test started by using the von Frey filament of
1.4 g corresponding to the middle mechanical force ap-
plied among the selected range of filaments (0.6–8.0 g).
A response (paw withdrawal) in at least three out of five
stimulations was considered positive. If a positive re-
sponse upon application of the 1.4 g filament force was
found, a lower weight filament (<1.4 g) was applied to
determine the response of the animal to the minimal
force applied (pain threshold). In the case of a negative
response upon application of the 1.4 g weight filament,
filaments of increasing force (>1.4 g) were applied until
the threshold was determined.
Only animals in which a pain threshold in at least one
hindpaw could be measured were plotted, resulting in a
lower number than in the BMS. The pain threshold was
considered not measurable when a filament force above
8 g was required to elicit a response.
Immunohistochemistry
Immediately after transcardial perfusion with 4 % PFA
(performed at DPO43), the columna vertebralis was ex-
cised from the mouse body and fixated in 4 % PFA over-
night. On the next day, the spinal cord was excised from
the columna vertebralis by cutting off the spines and
breaking off the bones. After PFA fixation overnight, PFA
was exchanged with 15 % sucrose followed by 30 % su-
crose (each for 1 day) until usage. Then 20 μm sagittal
sections were cryosectioned and directly mounted on
(SuperFrostPlus, Menzel, Braunschweig, Germany) slides.
For immunohistochemistry, sections were fixed in 4 %
PFA for 15 minutes, rinsed for 5 minutes in 0.2 % PBS-
TX, and incubated with 4 % goat serum for 15 minutes.
Sections were then incubated with primary antibodies
overnight at 4 °C in 4 % goat serum. The following
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primary antibodies were used: rabbit polyclonal anti-
microtubule-associated protein 2 (anti-MAP2; 1:200)
and monoclonal anti-oligodendrocyte transcription fac-
tor 2 (anti-Olig2, 1:100; both from Chemicon, Billerica,
MA, USA), rabbit polyclonal anti-glial fibrillary acidic
protein (anti-GFAP, 1:1000; Abcam, Cambridge, UK),
and rabbit polyclonal anti-aspartoacylase (anti-ASPA;
1:1000) and rabbit polyclonal anti-GFP (1:1000; kind
gifts from Matthias Klugmann, Sydney, Australia). After
3 × 5 minute 0.2 % PBS-TX washes, the sections were in-
cubated with the secondary antibody (goat anti-mouse
or anti-rabbit AlexaFluor546, 1:1000; Invitrogen) for
1 hour at room temperature. Then 3 × 5 minute 0.2 %
PBS-TX washes were performed. To double-stain with
an anti-BrdU antibody, slides (stained for all antibodies
except BrdU) were fixed again for 15 minutes in 4 %
PFA to stabilize antigen–antibody complexes. Sections
were then incubated in 1 N HCl for 1 hour at 37 °C to
denature DNA, followed by 3 × 10 minute PBS washes.
Sections were further incubated in blocking solution
containing 1 % donkey serum for 90 minutes. After
blocking, the incubation with the rat monoclonal anti-
BrdU antibody (1:100; Abcam) was performed over-
night at 4 °C. The second day, slides were rinsed for 3 ×
10 minutes with PBS before the sections were incubated
with the secondary antibody (goat anti-rat AlexaFluor647,
1:1000; Invitrogen) for 90 minutes, and then washed for
2 × 10 minutes with PBS. The background was reduced by
counterstaining with 0.05 % Sudan black for 5 minutes.
The sections were then washed with 70 % ethanol and
dH2O. Slides were mounted with Mowiol.
Microscopic analysis of histology
Slides were observed under a Leica DM5500 (Leica
Camera, Wetzlar, Germany) fluorescence microscope or a
Zeiss Axiovert LSM 710 (Carl Zeiss, Oberkochen, Germany)
laser scanning confocal microscope. For laser scanning con-
focal microscopy, z-stacks with optical sections of 2 μm of
the lesion core and adjacent regions were recorded.
Lesion volume and cell survival were assessed based
on the Cavalieri principle of stereology. To determine
the lesion volume, every 10th section of the spinal cord
was stained for the astrocytic marker GFAP and digital
photomicrographs were taken. The lesion cavity was
outlined and the area measured by ImageJ, National
Institutes of Health, Bethesda, MD, USA. Volume was
calculated by multiplying the measured area of each sec-
tion by the distance between the photographed sections.
Single volumes were then summed for a final estimation
of total lesion volume.
For quantification of cellular survival, the total number
of BrdU-positive cells was calculated. To avoid counting
the same cell in adjacent sections, every fifth section was
counted (100 μm apart).
To quantify the differentiation pattern of transplanted
cells, 100 BrdU cells per animal and specific costaining
were analyzed and colocalization with respective cell fate
markers in a 50 μm× 50 μm field was counted.
For analysis of anterograde tracing, the section with a
clearly recognizable end of the CST was used for the
analysis along with four additional adjacent sections.
BDA-labeled fibers were quantified at defined distances
(0.5 mm, 1 mm, and 2 mm) caudal from the lesion cen-
ter along the dorso-ventral axis. Labeled fibers are
shown as percentage of the total number of fibers at the
end of the CST. Only axons fulfilling the criteria of
Steward et al. [26] were included in the analysis.
Statistical analysis
Data are presented as the mean ± standard error of the
mean (SEM). The statistical analyzing was carried out
with GraphPad Prism 4 (Statcon, Witzenhausen,
Germany) and IBM SPSS Statistics 22v software (IBM
Corporation, Armonk, NY, USA). Differences in motor
behavior were tested using analysis of variance
(ANOVA) with repeated measures. The factors were cell
groups × time. Because this gave a significant interaction
with p <0.05, we further tested single days by one-way
ANOVA and consecutive post-hoc Tukey’s test (Fig. 4a).
Results of the von Frey filament test were analyzed by
one-way ANOVA (Fig. 4b).
To test differences in lesion volume, the nonparamet-
ric Kruskal–Wallis test followed by Dunn’s post-hoc
multiple comparison tests were applied (Fig. 5). When
comparing only two groups in immunohistology (BDNF-
GFP versus GFP transplants for each differentiation
marker or BrdU to assess cell survival), the two-tailed
unpaired Student’s t test was applied for all markers,
except ASPA (one-tailed) (Figs. 6c and 7b). One-way
ANOVA for each distance with consecutive post-hoc
Tukey’s test was used for anterograde tracing (Fig. 8d).
Differences were assumed to be significant if p <0.05;
nonsignificant differences are not indicated.
Results
In vitro differentiation and purification of ESCs
Mouse ESCs were differentiated into early neural pro-
genitor cells (NPCs), which express PSA-NCAM as a
marker. The protocol recapitulates early embryonic de-
velopment and consists of various differentiation steps,
including EB formation, selection, and expansion of
Nestin-positive cells (Fig. 1a).
On day 24 of differentiation, flow cytometric analysis
showed that 50.8 % of all cells were PSA-NCAM-
positive (Fig. 2a), and 5.07 % positive for SSEA-1
(Fig. 2b). To obtain a pure neural population for trans-
plantation, the PSA-NCAM-positive fraction was enriched
by MACS, and the undifferentiated ESCs positive for
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SSEA-1 were removed. After MACS, all cells were positive
for PSA-NCAM, and no SSEA-1-positive cells were de-
tected (Fig. 2a, b). Cells were analyzed after MACS on the
fluorescence-activated cell sorter, revealing that 99.9 % of
MACS-sorted cells were positive for PSA-NCAM and
negative for SSEA-1 (Fig. 3, quadrant analysis right
panels). To deplete single cells positive for SSEA-1, GFP
cells and BDNF-GFP cells were subjected to FACS, by
applying stringent sorting gates. As shown in Fig. 3a, b,
the gating strategy excluded debris and dead cells
(obtaining P1) and doublets (P2). The majority of the
population was PSA-NCAM+/SSEA-1–, but single cells
were excluded by setting very stringent gates in the
population (P3). Double FACS removed remaining
SSEA-1-positive cells, which can cause teratoma forma-
tion after transplantation. A total of 93.7 % BDNF-GFP
cells and 95.7 % GFP cells were sorted from the stained
cells, obtaining a pure cell population of PSA-NCAM-
positive neural progenitors.
To ensure cell detection in vivo, cells were labeled in
vitro with BrdU. Immunocytochemistry revealed that
BrdU uniformly labeled all sorted cells (Additional file 1:
Figure S1).
Improved motor function after transplantation of
BDNF-GFP neural progenitors
Purified PSA-NCAM+ neural progenitors were trans-
planted directly into the lesion core 7 days after contu-
sion SCI. At different DPO, motor behavior was assessed
using the BMS (experimental outline, Fig. 1b).
At DPO1, lesioned animals differed in their BMS
scores as they showed variations of their scores ranging
from 0.0 to 3.0. The scores on DPO1 showed a signifi-
cant influence on the scores for the remaining test days
DPO6–DPO42 (p <0.001 for DPO1 BMS score as a co-
variate in repeated-measures ANOVA for time (DPO6–
DPO42) and “transplantation group” (vehicle, GFP,
BDNF-GFP)). Therefore, for the final analyses, the BMS
scores for DPO6–DPO42 were normalized to the score
on DPO1 and expressed as delta BMS (subtraction of
DPO1 score). This resulted in the same delta BMS initial
score on DPO1 (delta BMS DPO1 = 0, for all groups).
BDNF-GFP cell transplanted animals displayed a sig-
nificantly improved motor function compared with GFP
cell transplanted or vehicle-treated mice (Fig. 4a). Aver-
aged delta BMS scores on DPO35 showed that BDNF-
GFP cell transplanted animals (2.86 ± 0.28) were on
Fig. 1 General scheme of ESC differentiation and experimental outline of study. a After two passages on gelatin, ESC differentiation started with
EB formation, followed by selection of Nestin+ cells in ITSFn medium and subsequent expansion in DMEM/F12 + B27 medium in the presence of
bFGF. On day 24 of differentiation, cells were purified by FACS and MACS to yield a population of SSEA-1–/PSA-NCAM+ progenitors, which were
labeled with BrdU for 48 hours prior to transplantation. b Transplantation was performed on DPO7, the surgery for biotin dextran tracing took
place on DPO21, and the von Frey filament test immediately before perfusion on DPO42. Motor behavior by BMS scoring was tested 1 day prior
to SCI (DPO–1) and on DPO1, 6, 8, 10, 14, 21, 28, 35, and 42. bFGF basic fibroblast growth factor, BrdU 5-bromo-2′-deoxyuridine, DMEM Dulbecco’s
modified Eagle’s medium, DPO days post operation, EB embryoid body, ESC embryonic stem cell, FACS, fluorescence-activated cell sorting, ITSFn
insulin, transferrin, selenium chloride, fibronectin, MACS magnetic-activated cell sorting, PSA-NCAM polysialylated neural cell adhesion molecule,
SCI spinal cord injury, SSEA-1 stage-specific embryonic antigen-1
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average 1.4 points higher scored than GFP cell trans-
planted animals (1.44 ± 0.38) with p = 0.02. On DPO42,
this difference became even more evident when BDNF-
GFP cell transplanted animals (3.0 ± 0.29) on average re-
vealed a 1.8 points higher score than GFP cell transplanted
animals (1.22 ± 0.38) with p = 0.005. BDNF-GFP cell trans-
planted animals also performed significantly better than
vehicle-treated mice (1.56 ± 0.33 on DPO42, p = 0.026).
Unexpectedly, animals transplanted with GFP-expressing
NPCs were not significantly different from vehicle-treated
mice. Sham group animals displayed negative delta BMS
scores, because on DPO1 BMS scores were higher than
on the following days tested, which after subtraction of
the DPO1 score resulted in negative delta BMS values.
BDNF-GFP-overexpressing NPCs do not alter pain sensation
As BDNF plays a role in pain modulation, we aimed at
proving that BDNF-GFP-overexpressing NPCs are not
inducing increased nociception and consequently are
not harmful. Therefore, we used the von Frey filament
test to assess mechanical allodynia in these mice
(Fig. 4b). Pain thresholds were determined in each paw
using the up–down method (see Methods). The average
of the stimulus intensity (filament weight in grams) that
induced the minimal nociceptive response (pain thresh-
old) was calculated for each experimental group and is
shown as an average of the right and left paws (Fig. 4b).
Results were analyzed by one-way ANOVA. No significant
differences among groups were detected (p = 0.2224). The
tendency of sham animals to respond to lower filament
weights than lesioned mice might be explained by the in-
jury itself. Contusion SCI can elicit sensory dysfunction
and therefore result in a slightly decreased pain threshold
in lesioned mice.
Most importantly, BDNF-GFP cell transplanted ani-
mals showed no significant changes in their mechanical
Fig. 2 Immunocytochemistry and flow cytometric analysis of NPCs before and after MACS and FACS. Before MACS, 50.8 % of all cells were
positive for PSA-NCAM (a) (pre sort) and 5.07 % positive for SSEA-1 (b) (pre sort). After MACS and FACS, immunofluorescence showed that cells
are positive for PSA-NCAM (a) (post sort) and negative for SSEA-1 (b) (post sort). DAPI 4′,6-diamidino-2-phenylindol, NPC neural progenitor cells,
PSA-NCAM polysialylated neural cell adhesion molecule, SSEA-1 stage-specific embryonic antigen-1
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pain threshold as compared with GFP cell transplanted
mice or the vehicle group. This leads to the conclusion
that an increase in BDNF levels, secreted from BDNF-
GFP-expressing NPCs in the lesioned spinal cord, does
not increase the pain sensation in mice.
BDNF-GFP NPCs reduce lesion volume in injured mice
Contusion injury led to a lesion of the spinal cord sur-
rounded by a glial scar. To investigate the potential
effect of transplanted NPCs on a histopathological par-
ameter, we assessed the lesion volume by staining for
the glial scar marker GFAP (Fig. 5). The lesion area was
defined as the area devoid of GFAP staining and out-
lined on photomicrographs (Fig. 5a). Vehicle-treated ani-
mals had an average lesion volume of 0.34 ± 0.11 mm3,
GFP NPC transplanted animals of 0.12 ± 0.01 mm3,
and BDNF-GFP NPC transplanted animals of 0.03 ±
0.002 mm3. The Kruskall–Wallis test (p = 0.01) with
Dunn’s post-hoc test revealed a significant reduction in
the BDNF-GFP cell group compared with the vehicle-
treated group (p = 0.007) (Fig. 5b). In contrast, even if
showing a trend, GFP NPCs did not lead to a statistical
significant reduction in lesion volume (p = 0.509).
Enhanced neuronal and oligodendrocytic in vivo
differentiation of BDNF-GFP NPCs
Animals were sacrificed by transcardial perfusion on
DPO43. To analyze in vivo differentiation of trans-
planted cells, double immunohistology on sagittal spinal
cord sections was performed with cell fate markers and
GFP and/or BrdU to trace transplanted cells (Fig. 6). In
contrast to GFP-expressing NPCs, transplanted NPCs
expressing BDNF-GFP were barely detectable by the
GFP signal, even when using an antibody against GFP.
This difference in GFP detection might be explainable
by the vesicular expression pattern of BDNF-GFP, which
Fig. 3 Purification of cells by FACS. BDNF-GFP-expressing cells (a) and GFP-expressing control cells (b) were sorted by FACS after MACS. The
analysis gates were set with reference to negative controls, resulting in a 99.9 % purity of all stained cells (Q3). Sorting gates were set as follows.
Left panels: the gate (P1) was set for cell size and granularity of the cells. Dead cells and cell debris (shown in black) were excluded. Middle panels:
the gate (P2) was set for single cell sorting. Cell doublets (shown in red) were excluded. Right panels show the stringent gate (P3) for the
PSA-NCAM sort. BDNF brain-derived neurotrophic factor, FSC forward scattering, GFP green fluorescent protein, PSA-NCAM polysialylated neural cell
adhesion molecule, SSC side scattering, SSEA-1 stage-specific embryonic antigen-1
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we already observed previously [19]. To ensure effective
cell tracing also in the BDNF-GFP group, transplanted
cells of both groups were labeled in vitro with BrdU
right before transplantation (Additional file 1: Figure
S1). BrdU staining of transplanted cells in spinal cord
sections showed that BDNF-GFP NPCs can efficiently
be traced with BrdU 5 weeks after transplantation
(Fig. 6a, upper panels).
Both GFP NPCs and BDNF-GFP NPCs integrated into
the spinal cord tissue and localized near the lesion site
(Fig. 6b). The initial graft contained 100,000 cells per
animal; stereological estimation revealed an average of
27.38 ± 4.94 % of BDNF-GFP cells and 21.74 ± 3.56 % of
GFP NPCs present 5 weeks following transplantation
(Fig. 6c). In general, these values demonstrate proper
cellular survival, which does not, however, exclude the
possibility of cell proliferation after transplantation. No
significant difference was detected between both trans-
plantation groups (p = 0.4066). Thus, expression of
BDNF-GFP in NPCs did not alter cellular survival after
grafting.
To determine the fate of transplanted neural progeni-
tors, antibodies against markers of all three neural cell
lineages were used in double stainings with antibodies
against BrdU. Figure 7a shows representative confocal
micrographs of grafted BrdU cells, which were positive
for the neuronal marker MAP2 or the astrocytic marker
GFAP. Furthermore, antibodies against the oligodendro-
cytic markers Olig2 and ASPA were used. Olig2 is well
known for determining oligodendrocyte differentiation,
whereas ASPA represents a marker for a later differenti-
ation status. Stained sections were analyzed by the LSM
710, and z-stacks of the lesion core were recorded. To
quantify lineage-specific differentiation, the percentage
of double-positive cells from all BrdU-positive cells was
analyzed. Quantitative assessment of NPC in vivo differ-
entiation in cell transplanted animals showed a tendency
for overall increased neural differentiation of BDNF-GFP
compared with GFP cells (Fig. 7b). BDNF-GFP neural
progenitors differentiated to a greater extent into
MAP2-positive neurons (14.5 ± 3.4 %) than GFP NPCs
(2.5 ± 1.45 %). Furthermore, differentiation into the oli-
godendrocytic lineage, assessed by Olig2 staining, was
significantly enhanced (9.5 ± 1.6 %) compared with GFP-
expressing NPCs (5.0 ± 1.6 %). No ASPA-positive BrdU-
labeled cells were found in GFP cell transplanted an-
imals. In contrast, BDNF-GFP cells (3.33 ± 1.54 %)
showed a low, but significant proportion in late oligo-
dendrocytic differentiation. Astrocytic differentiation
did not significantly differ between both groups. In
GFP transplanted grafts, astrocytic differentiation was
significantly favored over differentiation into MAP2-
positive neurons (p = 0.0067), whereas no significant
difference between the extent of astrocytic versus
Fig. 4 Behavioral assessments. a Analysis of delta BMS scores (calculated by subtraction of score from DPO1). The functional recovery of mice
with SCI after transplantation of BDNF-GFP cells, GFP cells, or infusion of vehicle (HBSS w/o Ca2+/Mg2+). The averaged delta BMS scores of the
three groups were analyzed via ANOVA with repeated measures (cell groups × time). This gave a significant interaction of cell groups × time of
p <0.05. Cell group differences were further investigated on single days (DPO35 and DPO42) by one-way ANOVA and consecutive post-hoc
Tukey’s test. DPO35, BDNF-GFP to GFP (*p = 0.02); DPO42, BDNF-GFP to GFP (**p = 0.005) and BDNF-GFP to vehicle (*p = 0.026). BDNF-GFP, n = 7;
GFP, n = 9; vehicle, n = 8; sham, n = 8. b Von Frey filament test, representing the average of the stimulus intensity (filament weight in grams) used
to determine pain threshold (paw withdrawal threshold) in each group, shown as the average of both hindpaws. BDNF-GFP, n = 4; GFP, n = 5;
vehicle, n = 5; sham, n = 8. The difference in the number among the animal groups is owing to the viability in the responsiveness of the animals
to the stimulus (see Methods for details). BDNF-GFP animals showed no statistically significant change in their mechanical pain threshold as compared
with the other groups. The four groups were analyzed by one-way ANOVA. No significant difference among the four groups was detected
(p = 0.2224). BDNF brain-derived neurotrophic factor, BMS Basso mouse scale, DPO days post operation, GFP green fluorescent protein
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neuronal differentiation of BDNF-GFP NPCs was de-
tected (p = 0.31).
To test whether transplanted NPCs positive for BrdU
but for none of the respective differentiation markers
remained in the NPC precursor stage, double staining of
BrdU and PSA-NCAM was performed. Double-positive
cells were detected in neither cell transplanted group
(data not shown), suggesting that NPCs were either
differentiating into a neural lineage state, which is not
detectable by the used markers, or had undergone
transdifferentiation.
BDNF-GFP transplanted NPCs enhance axonal fiber
outgrowth
BDA-traced CST fibers, used as a marker for axonal
plasticity, were analyzed in animals which had received
either BDNF-GFP cells, GFP NPCs, or vehicle (Fig. 8a–c).
Treatment of injured mice with BDNF-GFP-expressing
NPCs revealed a significantly higher number (37.25 ±
6.42 %) of BDA-positive fibers than in GFP cell-treated
(14.00 ± 4.92 %) or vehicle-treated (9.00 ± 4.85 %) animals
0.5 mm caudal to the lesion site (Fig. 8d). Further distal
to the lesion core, at 1 and 2 mm, a similar trend for
increased axonal growth induced by BDNF-GFP NPCs
was observed. At 2 mm distance caudal to the lesion
center, BDA-traced fibers were not detectable anymore
in GFP cell-treated or vehicle-treated mice. Further-
more, GFP NPCs did not show any significant improve-
ments of axonal growth compared with vehicle treatment.
Altogether, besides the detected effects on stem cell differ-
entiation (see in vivo differentiation of NPCs), BDNF-GFP
NPCs were proven to be additionally beneficial by enhan-
cing axonal plasticity in contusion SCI.
Discussion
In recent years, approaches for treatment of SCI have fo-
cused on so-called “combination therapies” which com-
bine modestly effective individual therapies, leading to
an enhanced effect when used together [27]. In our ap-
proach, we combined the use of predifferentiated ESCs
which continuously secrete the neurotrophin BDNF,
thus linking cell replacement with neurotrophic supply.
BDNF is one of the most studied and promising growth
factors for SCI therapy. In rodent animal models, BDNF
appears to increase motor functioning shortly after in-
jury [28, 29]. Neural differentiated ESCs transplanted
Fig. 5 Analysis of lesion volume in injured mice. a Representative micrographs of GFAP-stained sections from BDNF-GFP cell-treated, GFP
cell-treated, or vehicle-treated spinal cord, showing the center of the lesion. Lesion cavity was determined by negative GFAP staining and outlined
(dotted lines). b Quantitative analysis of lesion volume showed a significant reduction in the BDNF-GFP cell group compared with the vehicle-treated
group (p = 0.007), but not in the GFP group compared with the vehicle-treated group (p = 0.509). The average of n = 4 mice ± SEM is presented
with **p <0.01, Kruskal–Wallis test with Dunn’s post-hoc test. BDNF brain-derived neurotrophic factor, GFAP glial fibrillary acidic protein,
GFP green fluorescent protein
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into the injured rodent spinal cord have been shown to
differentiate into astrocytes, oligodendrocytes, and neu-
rons, and have been associated with moderate locomotor
recovery [3, 5, 6, 30]. Here, we show that ESC-derived
neural progenitors, genetically engineered to overexpress
BDNF, promote functional recovery in a mouse model of
contusion SCI as compared with control cells. In a pre-
vious study, we addressed in vitro differentiation of these
recombinant ESCs and observed an enhanced neuronal
differentiation after retinoic acid treatment of EBs [19].
A
B C
Fig. 6 Detection of transplanted NPCs in the spinal cord. a Confocal micrographs of grafts of neural progenitors expressing BDNF-GFP (upper panel) or
GFP (lower panel) 5 weeks after cell transplantation in low magnification. GFP cells are positive for BrdU and showed robust GFP expression. However,
the GFP signal of BDNF-GFP-expressing cells is very weak and almost undetectable by confocal microscopy, but cells can be efficiently traced by BrdU.
b Maximum intensity projection of a 20 μm section of a BDNF-GFP cell and GFP cell graft in the spinal cord. BrdU labeled-cells (green) are localized
near the injury lesion (GFAP negative). c Quantification of cell survival in NPC grafted mice: 27.38 ± 4.94 % BDNF-GFP NPCs and 21.74 ± 3.56 % GFP
NPCs of 100,000 injected cells were detectable 5 weeks after transplantation. No significant difference was detected among the groups (p = 0.4066),
unpaired Student’s t test. Data represent mean ± SEM. BDNF brain-derived neurotrophic factor, BrdU 5-bromo-2′-deoxyuridine, GFAP glial fibrillary acidic
protein, GFP green fluorescent protein
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In order to treat SCI contusion in mice, the protocol
was changed to a distinct differentiation protocol obtain-
ing early PSA-NCAM-positive neural progenitors (modi-
fied from [21]). These cells were purified by different
cell sorting techniques, involving MACS followed by a
FACS fine sort to yield a highly pure population of
NPCs. Basically, a depletion of remaining tumorigenic
SSEA-1-positive undifferentiated ESCs was performed
with a subsequent enrichment for PSA-NCAM-positive
cells. Consequently, we did not observe any tumor for-
mation or overgrowth after transplantation, which are
key concerns after induced pluripotent stem cell (iPSC)/
ESC-derived grafting [31, 32].
PSA-NCAM-positive NPCs survived grafting and were
detectable 5 weeks after transplantation. As the trans-
planted early neural precursors were multipotent [20], we
could show that they differentiated in vivo into all three
neural lineages. In general, BDNF-GFP-overexpressing
cells showed an increase in neural differentiation com-
pared with GFP-expressing cells. Particularly, the percent-
age of MAP2-positive neurons and Olig2 oligodendrocytic
precursor cells was significantly higher than in grafts de-
rived from GFP-expressing cells. In addition, no ASPA-
positive cells were detected in GFP cell grafts. This was in
contrast to BDNF-GFP-overexpressing NPCs, where a
small, but significant, proportion of cells differentiated
into the late oligodendrocytic stage. The enhanced neur-
onal and oligodendrocytic differentiation of BDNF-GFP-
overexpressing NPCs is of particular importance and
might explain, at least in part, the improved motor func-
tion in these animals [30]. In general, poor differentiation
into neurons and oligodendrocytes was detected when
transplanting NPCs. Instead, a strong astrocytic differenti-
ation was observed [33, 34], which might hinder consider-
able functional recovery, similar to that we observed after
transplantation of GFP control cells. Our data provide evi-
dence for BDNF-induced NPC differentiation into both
favored lineages in vivo, leading to cell replacement of
damaged neurons and oligodendrocytes. We and others
have already shown that BDNF enhances neuronal differ-
entiation, as it is known to support differentiation of em-
bryonic, mesenchymal, and NSCs into neurons in vitro
and in vivo [8–10, 19]. Furthermore, BDNF is important
for oligodendroglial proliferation, differentiation, and
myelination [11–13]. Therefore, in terms of cell replace-
ment in SCI, our results demonstrate PSA-NCAM pro-
genitors with a stable secretion of BDNF to be a more
potent cellular source than PSA-NCAM (GFP-expressing)
progenitors without neurotrophin supply. A remaining
question is why transplantation of GFP-expressing NPCs
did not enhance functional improvement compared with
vehicle treatment, as has been described for other ESC-
derived cell transplants into the spinal cord in other inves-
tigations [3, 6]. One explanation could be the different di-
rected differentiation and/or the purification of ESCs used
in our study. In the aforementioned studies, ESCs were
only roughly predifferentiated by EB formation and retin-
oic acid treatment and were transplanted without further
purification. The definite injected cell population then
remained unclear. However, it is possible that a mixture of
non-neural cells and NSCs/NPCs in different stages of dif-
ferentiation was advantageous to exert a functional effect
[35]. Underlying mechanisms could be either a better
differentiation potential of transplanted progenitors or
higher cellular survival. In addition, it was reported that
overexpression of GFP may generate free radicals, which
are toxic to the cell and can lead to apoptosis [36]. How-
ever, when we addressed cell survival in our study, we
found no significant difference between both transplanted
populations and the rate of cell survival appeared normal,
when compared with other studies [37, 38]. Nonetheless,
lesion size appeared to be differentially affected between
both groups. Only BDNF-GFP NPC grafts significantly
reduced lesion volume compared with vehicle-treated
animals, which underlines the therapeutic effect of
BDNF-expressing NPCs based on the behavioral out-
come. GFP cells did not ameliorate motor function and
only displayed a small, nonsignificant tendency to re-
duce lesion size.
With our combination therapy approach, we not only
aimed for an enhanced/shifted differentiation potential
of NPCs overexpressing BDNF, but also for a positive
effect on host axonal plasticity by constitutive BDNF
secretion. Other studies have demonstrated BDNF-
induced axonal regrowth in the presence of a fibroblast
or bone marrow stromal cell graft, indicating that BDNF
is capable of affecting such regeneration in a suitable
environment [17, 39, 40].
(See figure on previous page.)
Fig. 7 In vivo differentiation of transplanted neural progenitors. a Representative confocal micrographs of transplanted BrdU+ BDNF-GFP or GFP
cells, which are positive for MAP2, GFAP, Olig2, or ASPA. b Quantitative analysis of neural progenitor differentiation. Z-stacks were recorded with a
confocal laser scanning microscope. Cells positive for BrdU and the respective marker were counted in a 50 μm× 50 μm wide field. BDNF-GFP
neural progenitors showed a significant increase towards neuronal (MAP2+, p = 0.0088) and oligodendrocytic (Olig2+, p = 0.0418; ASPA+, p = 0.029)
lineage differentiation. Astrocytic differentiation (GFAP+) was not significantly changed (p = 0.1783) as compared with GFP-expressing neural
progenitors. The average of n = 6 ± SEM transplanted animals is represented. *p <0.05 and **p <0.01, unpaired Student’s t test. Transplants with
GFP cells revealed a bias towards astrocytic over neuronal differentiation (##p = 0.0067). ASPA aspartoacylase, BDNF brain-derived neurotrophic
factor, BrdU 5-bromo-2′-deoxyuridine, GFAP glial fibrillary acidic protein, GFP green fluorescent protein, MAP2 microtubule-associated protein 2,
Olig2 oligodendrocyte transcription factor 2
Butenschön et al. Stem Cell Research & Therapy  (2016) 7:11 Page 13 of 17
Fig. 8 (See legend on next page.)
Butenschön et al. Stem Cell Research & Therapy  (2016) 7:11 Page 14 of 17
Indeed, we were able to show an increase of BDNF-
induced axonal plasticity as compared with control cells
with our results of CST anterograde axonal tracing.
Based on morphological criteria [26, 41], BDA-positive
fibers counted caudal to the lesion appeared to present
newly formed fibers. However, due to characteristics of
contusion injury, we cannot exclude a small percentage of
(undetected) sparing. Hence, counted fibers could present
a mixture of newly established fibers derived from the site
of the lesion and of those sprouting from uninjured fibers,
as already described in other studies [42].
To our knowledge, no study has clearly demonstrated
growth of corticospinal axons caudal to the lesion site
after grafting BDNF-secreting cells. Only in one study
was sprouting reported when transplanting BDNF-
hypersecreting mesenchymal stem cells, which already
had a positive effect on functional outcome [43]. The
study of CST growth is particularly important, as this
motor projection is critical for human voluntary motor
function [41]. So far, only the transduction of fibroblast
grafts with neurotrophin-3 led to growth of corticospinal
axons and modestly improved functional deficits in SCI
[44, 45]. The effect of BDNF on axonal regrowth in
other studies [39] could only provide evidence for gen-
eral axonal regeneration (traced by neurofilament-M
staining) and regrowth of rubrospinal neurons [40]. The
outcome on motor function was not assessed in either
of these studies. In another study where axonal regrowth
of spinal motor and sensory neurons was supported, no
functional improvement was detected when using trans-
plants of marrow stromal cells overexpressing BDNF
[17]. Altogether, we assume that particularly the re-
growth of CST axons is important to enhance functional
improvement, at least in rodent models of SCI. Why this
was evident in our approach and not when transplanting
marrow stromal cells overexpressing BDNF [17] could
be because we observed a combinatorial effect of ESC-
derived precursors and BDNF secretion. It is assumable
that neural progenitor grafts create a better neuroprotec-
tive environment than marrow stromal cells; for ex-
ample, by secretion of a cocktail of growth factors and
other neurotrophins different from BDNF.
One major concern when transplanting BDNF-
overexpressing NPCs into the lesioned spinal cord is a
potential increase in neuropathic pain, which would
represent a severe side effect of the therapy approach
applied here. Indeed, transplantation of NSCs has been
shown to improve motor function, but also to induce allo-
dynia in SCI lesioned rats. This effect has been attributed
to prevalent astrocytic differentiation and thereby en-
hanced axonal sprouting, presumably due to secretion of
neurotrophins [46]. In general, growth factor delivery has
been reported to enhance pain sensitivity in response to
non-noxious stimuli in diverse neuropathologies [47–49].
BDNF is one of the neurotrophic factors that have been
associated with the development of neuropathic pain [50].
Furthermore, it has been reported that increased BDNF in
spinal cord following peripheral nerve damage could re-
sult in hyperalgesia in mice [51]. Moreover, BDNF is
known to participate in regulating central sensitization
and to induce neuropathic pain after SCI [52, 53]. Using
the von Frey filament test, we assessed the occurrence of
mechanical allodynia in mice after transplanting PSA-
NCAM progenitors overexpressing BDNF-GFP or GFP as
control. We did not detect any difference in pain thresh-
old between vehicle-treated and both NPC-treated groups,
suggesting that neither the transplantation of NPCs nor
the overexpression of BDNF led to alterations in nocicep-
tion in these mice. The discrepancy between our study
and the data reported by Hofstetter et al. [46] may be
caused by the fact that we used further differentiated
neural cells, and that PSA-NCAM-positive progenitors
are less harmful than naïve NSCs and thus have less im-
pact on affecting pain sensitivity in mice. Our BDNF over-
expression, which leads to approximately eight times
higher levels than the endogenous BDNF in ESC-derived
differentiated neurons [19], is therefore a moderate over-
expression, which does not appear to induce the develop-
ment of allodynia.
Conclusions
The use of BDNF-overexpressing PSA-NCAM-positive
NSCs is a conceivable therapeutic approach for the
treatment of incomplete SCI. BDNF promoted NPC dif-
ferentiation into favored neuronal and oligodendrocytic
cells and promoted host axonal plasticity. Both effects
resulted in an improved motor recovery without indu-
cing allodynia or tumor formation.
(See figure on previous page.)
Fig. 8 Anterograde tracing of the CST. Overview of confocal micrographs of sagittal sections showing the area of the spinal cord between the
CST end and 2 mm caudal to the lesion center (LC) of a transplanted BDNF-GFP NPCs, b transplanted GFP NPCs, and c vehicle-treated animals.
Pictures below the main panels show details by higher magnification z-stack micrographs of representative areas at 0.5, 1 and 2 mm distance
from the LC. White squares in the overview images show higher magnification panels of the respective end of the CST. d Quantification of
BDA-positive CST fibers. The quantity of CST fibers at 0.5 mm distance was significantly elevated in animals transplanted with BDNF-GFP as
compared with animals transplanted with GFP NPCs (p = 0.035) or compared with vehicle-treated animals (p = 0.035). The average of n = 4
mice (four adjacent sections per mouse) ± SEM is presented with *p <0.05, one-way ANOVA comparing three groups for each distance with
consecutive post-hoc Tukey’s test. BDA biotinylated dextran amine, BDNF brain-derived neurotrophic factor, GFP green fluorescent protein
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In future, the validity of our combinatorial therapeutic
approach could be evaluated with iPSCs overexpressing
BDNF, which recently have been produced from rats and
used to modulate stress-related pathology [54]. However,
those cells have not been transduced by targeted BDNF
gene transfer using homologous recombination as we used
[19]. Gene targeting is a much safer approach, avoiding
unwanted random integration, which might affect genome
function.
Additional file
Additional file 1: Figure S1. Efficient BrdU labeling and in vitro
detection of sorted neural progenitors. A Representative bright-field
(BF) image showing sorted PSA-NCAM-positive cells. B BrdU
treatment resulted in a uniform fluorescent staining of the nuclei (blue).
C All cells were positively labeled with BrdU (merge image). (PDF 3019 kb)
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